An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension.

Autor: Simon, Marc A.¹ (AUTHOR) Marc.Simon@ucsf.edu, Hanrott, Kate² (AUTHOR), Budd, David C.² (AUTHOR), Torres, Fernando³ (AUTHOR), Grünig, Ekkehard⁴ (AUTHOR), Escribano‐Subias, Pilar⁵ (AUTHOR), Meseguer, Manuel L.⁶ (AUTHOR), Halank, Michael⁷ (AUTHOR), Opitz, Christian^8,9 (AUTHOR), Hall, David A.² (AUTHOR), Hewens, Deborah² (AUTHOR), Powley, William M.² (AUTHOR), Siederer, Sarah² (AUTHOR), Bayliffe, Andrew^2,10 (AUTHOR), Lazaar, Aili L.¹¹ (AUTHOR), Cahn, Anthony² (AUTHOR), Rosenkranz, Stephan¹² (AUTHOR)

Publikováno v: Pulmonary Circulation. Jan-Mar2022, Vol. 12 Issue 1, p1-15. 15p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

Autor: Simon, Marc A, Hanrott, Kate, Budd, David C, Torres, Fernando, Grünig, Ekkehard, Escribano-Subias, Pilar, Meseguer, Manuel L, Halank, Michael, Opitz, Christian, Hall, David A, Hewens, Deborah, Powley, William M, Siederer, Sarah, Bayliffe, Andrew, Lazaar, Aili L, Cahn, Anthony, Rosenkranz, Stephan

Publikováno v: Pulmonary circulation, vol 12, iss 1

Preclinical and early clinical studies suggest that angiotensin-converting enzyme type 2 activity may be impaired in patients with pulmonary arterial hypertension (PAH); therefore, administration of exogenous angiotensin-converting enzyme type 2 (ACE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::5786579ef86f73c5fdbc6fba6f93dbe1
https://escholarship.org/uc/item/4k2476jb